Skip to main content
. Author manuscript; available in PMC: 2020 Aug 31.
Published in final edited form as: Nat Rev Clin Oncol. 2012 Jan 31;9(3):178–183. doi: 10.1038/nrclinonc.2011.217

Figure 3 |.

Figure 3 |

Kaplan–Meier plot of two studies that led to registration of the respective drugs in renal cell carcinoma. a | sorafenib and b | sunitinib. Permission obtained from Massachusetts Medical Society part a © Escudier, B. et al. N. Engl. J. Med. 356, 125–134 (2007) and part b © Motzer, R. J. et al. N. Engl. J. Med. 356, 115–124 (2007).